NEW YORK (TheStreet) -- Shares of Puma Biotechnology
(PBYI) are up an astounding 275% in early Wednesday trading, making it the focal point on CNBC's "Cramer's Mad Dash" segment.
TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said the company reported a "remarkable number" when it came to its breast cancer treatment trial.
Fair-Trade Coffee Wins Over Starbucks, Keurig, but Fails Coffee Producers
Coca-Cola Looks to Crowdfunding to Raise Social Media Awareness
Greenberg: Ackman's 'Anticappointment'
Apple Q3 Earnings Live Blog Recap
The Phase III test consisted of 2,821 women, 33% of whom walked away as disease-free survivors.
"This is why it's so hard" to value biotech stocks, Cramer concluded, in reference to Fed
chair Janet Yellen's recent remarks about small-cap biotech companies having a stretched valuation.
-- Written by Bret Kenwell in Petoskey, Mich.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts